Everything below concerns epitalon. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not an approved drug | Marketed in most countries as a research chemical |
| Main literature language | Russian and English | Early reports concentrated in Russian journals |
| Typical stated purity | ≥95% by HPLC | Supplier declaration, seldom independently verified |
| Principal studied endpoint | Telomerase activity in vitro | Measured in cultured human cells |
| Reported administration routes | Subcutaneous, intranasal | Described in exploratory use reports |
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
An exopeptidase is any peptidase that catalyzes the cleavage of the terminal (or the penultimate) peptide bond; the process releases a single amino acid, dipeptide or a tripeptide from the peptide chain. Depending on whether the amino acid is released from the amino or the carboxy terminal (N-terminus or C-terminus), an exopeptidase is further classified as an aminopeptidase or a carboxypeptidase, respectively. Thus, an aminopeptidase, an enzyme in the brush border of the small intestine, will cleave a single amino acid from the amino terminus, whereas carboxypeptidase, which is a digestive enzyme present in pancreatic juice, will cleave a single amino acid from the carboxylic end of the peptide. Some examples of exopeptidases include:
During the course of World War I and the Turkish War of Independence, Turkish authorities enslaved over 500,000 Armenians and Greeks—primarily men, but also women and children—into labour battalions, as part of the Armenian genocide and the Greek genocide. Enslaved people forced into labour battalions often died quickly and under crippling conditions in quarries, mines, and roads, or were killed by their Turkish guards. In 1921, Turkish authorities made false birth certificates declaring Greek orphans to be older than they actually were. In this way, children were also conscripted into labour battalions. In 1922, Herbert Adams Gibbons relayed a report by the Near East Relief to the U.S. Secretary of State Charles Evans Hughes, which warned that the Greeks were in a condition "worse than slavery", while Mark Lambert Bristol reported that the Greek men in labour battalions were "treated like animals." The brutal conditions in these battalions resulted in a very high death rate among victims, reaching from 80% to as high as 99%.
=== Synthetic glycerol === Although more expensive than production from plant or animal triglycerides, glycerol can be synthesized by various routes. During World War II, synthetic glycerol processes became a national defense priority because it is a precursor to nitroglycerin. Epichlorohydrin is the most important precursor. Chlorination of propylene gives allyl chloride, which is oxidized with hypochlorite to dichlorohydrin, which reacts with a strong base to give epichlorohydrin. Epichlorohydrin can be hydrolyzed to glycerol. Chlorine-free processes from propylene include the synthesis of glycerol from acrolein and propylene oxide.
Sources: en.wikipedia.org
Modimelanotide (INN; development code AP-214, ABT-719, and ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued.
=== Fijian === A man by the name of Levani Mavoa from the village of Vadravadra on Gau Island is reported to have the longest name in Fiji and possibly the world. His full surname is Mavoaiuluivitimaitaveunienanodralakicakacakatakanavalenilotunagonenivadravadraenaesitetimaiuraqaicuruvularuaenavaleniveivakabulaimaiwaiyevoenayasanakocakaudrove, which is 160 letters long. His surname translates to "injured while on Taveuni when the people of Vadravadra went to work at Ura Estate where he got injured and was later admitted for two months at the Waiyevo Hospital in the province of Cakaudrove".
Eukaryotic cells are structurally complex, and by definition are organized, in part, by interior compartments that are themselves enclosed by lipid membranes that resemble the outermost cell membrane. The larger organelles, such as the nucleus and vacuoles, are easily visible with the light microscope. They were among the first biological discoveries made after the invention of the microscope. Not all eukaryotic cells have each of the organelles listed below. Exceptional organisms have cells that do not include some organelles (such as mitochondria) that might otherwise be considered universal to eukaryotes. The several plastids including chloroplasts are distributed among some but not all eukaryotes. There are also occasional exceptions to the number of membranes surrounding organelles, listed in the tables below (e.g., some that are listed as double-membrane are sometimes found with single or triple membranes). In addition, the number of individual organelles of each type found in a given cell varies depending upon the function of that cell. The cell membrane and cell wall are not organelles.
eV, higher than what is predicted in theory for continuum plates of the same thickness, due to nonlocal microstructural constraints such as nonlocal coupling of particle rotational degrees of freedom. On the other hand, resistance to bending is found to be greatly reduced in nanoparticle monolayers that are supported at the air/water interface, possibly due to screening of ligand interactions in a wet environment.
Sources: en.wikipedia.org
=== Genome === The genome of Pseudomonas aeruginosa consists of a relatively large circular chromosome (5.5–6.8 Mb) that carries between 5,500 and 6,000 open reading frames, and sometimes plasmids of various sizes depending on the strain. Comparison of 389 genomes from different P. aeruginosa strains showed that just 17.5% is shared. This part of the genome is the P. aeruginosa core genome.
Reproductive disorders are thought to be caused by nutritional deficiencies, particularly zinc, iron, folate, and selenium deficiencies in coeliac disease. Coeliac disease often affects the liver, causing increased transaminase levels. This elevation of transaminases seen in coeliac disease is known as coeliac hepatitis. Mildly increased transaminases without symptoms and without other possible factors such as autoimmune or viruses that could cause liver abnormalities, characterise coeliac hepatitis. In patients with persistent symptoms despite treatments for coeliac disease, IgE-mediated allergic diseases, including food allergy, allergic rhinitis, and asthma, should be considered in the differential diagnosis, as they may coexist with celiac disease. Due to the systemic nature of coeliac disease and its potential to affect any organ, there are many rarer presentations of coeliac disease, some of which have an unclear relationship to the disease. Some of these more uncommon manifestations include peripheral neuropathy, epilepsy, psoriasis, recurrent aphthous stomatitis, pericardial effusion, and Lane-Hamilton syndrome.
== Clinical Significance == Deficiency of glutaryl-CoA dehydrogenase causes glutaric acidemia type 1, an autosomal recessive metabolic disorder.In this disorder, impaired metabolism of glutaryl-CoA is associated with elevated levels of organic acids, including glutaric acid and 3-hydroxyglutaric acid .
Sources: en.wikipedia.org
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.
The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.
It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.
It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.